COVID-19 Drug Associated APIs Market Report 2026

The COVID-19 drug associated apis market size has grown strongly in recent years. It will grow from $7.14 billion in 2025 to $7.55 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to initial surge in COVID-19 cases, urgent need for repurposed drugs, limited availability of antiviral apis, dependency on imports from asia-pacific, accelerated emergency approvals.

The COVID-19 drug associated apis market size is expected to see strong growth in the next few years. It will grow to $9.69 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to development of next-generation antiviral and immunomodulator apis, expansion of domestic api manufacturing, increasing adoption of biotech synthesis, rising government funding for pandemic preparedness, growing demand for diversified COVID-19 treatment options. Major trends in the forecast period include rising demand for antiviral and antimalarial apis, increased focus on captive and merchant api manufacturing, expansion of synthetic and biotech-based api production, growing investment in research and development for COVID-19 drugs, enhanced regulatory oversight on api quality and supply chains.

Government initiatives supporting research and development in healthcare are expected to drive the growth of the COVID-19 drug-associated active pharmaceutical ingredient (API) market in the coming years. Government initiatives include targeted actions, programs, policies, or projects implemented at local, regional, national, or international levels to address specific challenges and achieve defined objectives. Investment in healthcare research and development is increasing as governments aim to stimulate innovation and accelerate the discovery of new therapies that address critical public health needs. COVID-19 drug-associated APIs support these initiatives by supplying essential active ingredients required for the rapid development, testing, and large-scale production of COVID-19 treatments and vaccines. For example, in April 2025, according to the Office for National Statistics, a UK government agency, government net expenditure on research and development reached £17.4 billion ($20.1 billion) in 2023, up from £16.1 billion in 2022. Therefore, increasing government initiatives for healthcare research and development are contributing to the growth of the COVID-19 drug-associated API market.

Major companies operating in the COVID-19 drug-associated API market are increasingly focusing on the launch of innovative products, such as oral COVID-19 treatments, to strengthen their competitive position. Oral COVID-19 treatments are medications administered by mouth to treat infections caused by the SARS-CoV-2 virus. For instance, in May 2023, Pfizer Inc., a US-based pharmaceutical company, launched PAXLOVID following approval by the U.S. Food and Drug Administration. This oral investigational therapy, a SARS-CoV-2 protease inhibitor, demonstrated an 89% reduction in the risk of hospitalization or death compared with placebo in high-risk, non-hospitalized adults with COVID-19. Intended for early use at the onset of symptoms or upon known exposure, the treatment is designed to help prevent severe disease, hospitalization, and mortality.

In January 2023, Sterling Pharma Solutions, a US-based pharmaceutical company, acquired an active pharmaceutical ingredient manufacturing facility from Novartis AG for an undisclosed amount. Through this acquisition, Sterling expanded its API manufacturing capacity, and the accompanying long-term supply agreement with Novartis enables continued production of several APIs used in cardiovascular, immunology, and oncology therapies. Novartis AG is a global pharmaceutical company involved in the manufacture of active pharmaceutical ingredients.

Major companies operating in the COVID-19 drug associated apis market are Dr. Reddy's Laboratories Ltd., Lianyungang Guike Pharmaceutical CO. LTD., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical Co. Ltd., Zhejiang Yatai Pharmaceutical Co. Ltd., Zhejiang Guobang Pharmaceutical Co Ltd., Cipla Limited, Shandong Boyuan Pharmaceutical Co. Ltd., Aspiro Pharma Ltd., Qilu Antibiotics Pharmaceutical Co. Ltd., Shenzhen China Resources Jiuxin Pharmaceutical Co. Ltd., Zhejiang Cheng Yi Pharmaceutical, Star Lake Bioscience Co.Inc., Hetero Labs Ltd., Geno Pharmaceuticals Ltd., Mylan Laboratories Ltd., Ipca Laboratories Limited, Zydus Takeda Healthcare Private Limited, Mangalam Drugs & Organics, Wallace Pharmaceuticals, Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd., Zhejiang NHU Co. Ltd., Zhejiang Xianju Pharmaceutical Co. Ltd., Zhejiang Yongtai Technology Co. Ltd., Zhejiang Zhebei Pharmaceutical Co. Ltd., Zhejiang Tianyu Pharmaceutical Co. Ltd., Zhejiang Aisheng Pharmaceutical Co. Ltd., Zhejiang Aokang Pharmaceutical Co. Ltd.

North America was the largest region in the COVID-19 drug-associated APIs market in 2025. Middle East is expected to be the fastest growing region in the global COVID-19 drug associated APIs market share during the forecast period. The regions covered in the COVID-19 drug associated apis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the COVID-19 drug associated apis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the COVID-19 drug-associated APIs market by increasing the cost of imported raw materials, active pharmaceutical ingredients, and precursors required for antiviral, antimalarial, and antibiotic drugs. Segments such as synthetic APIs and captive API manufacturing are most affected, with North America, Europe, and Asia-Pacific regions facing significant import duties. While tariffs have increased production costs and caused supply chain disruptions, they have also incentivized local API manufacturing, innovation in synthetic and biotech production, and long-term diversification of the supply base.

The COVID-19 drug associated apis market research report is one of a series of new reports that provides COVID-19 drug associated apis market statistics, including COVID-19 drug associated apis industry global market size, regional shares, competitors with a COVID-19 drug associated apis market share, detailed COVID-19 drug associated apis market segments, market trends and opportunities, and any further data you may need to thrive in the COVID-19 drug associated apis industry. This COVID-19 drug associated apis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

COVID-19 drug-associated APIs refer to the active pharmaceutical ingredients used in the manufacture of medications for the treatment of COVID-19. Active pharmaceutical ingredients are chemical substances that form the core of pharmaceutical drugs and are responsible for their pharmacological effects in the human body.

The primary classes of drugs in COVID-19 drug-associated APIs include antimalarials, bronchodilators, antibiotics, antivirals, and others. Antimalarial drugs are antiparasitic chemical agents used to treat or prevent malaria and are generally derived from organic sources. These APIs are available in both generic and branded forms and are produced through different business models such as captive API manufacturing and merchant API production.

The COVID-19 drug-associated APIs market consists of sales of acetaminophen (Tylenol) and ibuprofen (Motrin, Advil). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.